Tuberculosis causes more extensive and life-threatening disease in patients with HIV infection than in immunocompetent persons.
Introduction
Tuberculosis caused an estimated 3.3 million deaths in 1992, prompting the World Health Organization to declare a global public health emergency. The manifestations of tuberculosis in HIV-infected patients are much more severe than in immunocompetent persons, characterized by frequent extrapulmonary and miliary disease, mycobacteremia, and high mortality rates (1, 2) . This highly susceptible population has fueled deadly outbreaks of multidrug-resistant tuberculosis that are poorly responsive to standard chemotherapy (3) (4) (5) . Development of adjunctive therapy to modulate antimycobacterial host defenses hinges on an improved understanding of the alterations in the immune response in patients coinfected with Mycobacterium tuberculosis and HIV.
Immunologic resistance and susceptibility to intracellular pathogens in animals are mediated by CD4+ T cells with specific pattems of cytokine secretion. Thl cells that produce interferon-y confer resistance to Leishmania infection, whereas Th2 cells that produce IL-4 exacerbate disease severity (6, 7) . In patients infected with Mycobacterium leprae, type 1 cells that produce IFN-y and IL-2 predominate in tuberculoid leprosy patients with a resistant immune response, whereas type 2 cells producing IL-4 and IL-10 are dominant in lepromatous leprosy patients with ineffective immunity (8) . The clinical manifestations of tuberculosis are also thought to reflect the immune response to infection (9) . Advanced pulmonary tuberculosis represents an ineffective immune response, characterized by extensive and life-threatening disease and a high frequency of negative tuberculin skin tests. In contrast, patients with tuberculous pleuritis mount a resistant immune response, with spontaneous resolution of disease without therapy and a high frequency of positive tuberculin skin tests (10, 11) . The type 1 cytokines IFN-y and IL-2 predominate at the site of disease in patients with pleuritis (12) , but the pattem of cytokine production in patients with advanced pulmonary tuberculosis is uncertain. We hypothesized that the severe manifestations of tuberculosis in HIV-infected persons are due to alterations in the balance of T cell cytokines, and therefore evaluated the cytokine profile in patients coinfected with HIV and M. tuberculosis.
Methods
Patient population. Blood was obtained from 49 patients with their first episode of culture-proven tuberculosis. Acid-fast stains of sputum were positive in all patients. 23 patients had antibodies to HIV confirmed by Western blot, and 26 patients had negative ELISA tests for HIV antibody. The mean CD4 cell count in the HIV-infected patients was 126±49/Ml, and that in patients without HIV infection was 545±218/ M1. All patients had received less than two weeks of antituberculosis therapy at the time that blood samples were obtained.
Immunologic classification of patients. Patients with HIV infection were classified by a modification of methods outlined by Clerici et al. (13) . PBMC were isolated by differential centrifugation over FicollPaque (Pharmacia Fine Chemicals, Piscataway, NJ), and plated in 200 yld flat-bottomed wells at 2 x 105 cells/well in RPMI (GIBCO, Grand Island, NY) containing penicillin/streptomycin (GIBCO) and 10% heat-inactivated human serum. PBMC were cultured in triplicate in the presence of (a) media alone; (b) heat-killed M. tuberculosis Erdman Isolation of RNA and cDNA synthesis. Cells stimulated with M. tuberculosis were harvested after 24 h, lysed with 4 M guanidinium isothiocyanate, and stored at -20°C before preparation of RNA, which was isolated as described (15) . In some cases, purified CD4 + or CD8 + cells were isolated from M. tuberculosis-stimulated cells by incubation with magnetic beads conjugated to anti-CD4 or to anti-CD8 (Dynal International, Skoyen, Norway), and passage through a magnetic activated cell sorter (Miltenyi Biotec, Bergisch-Gladbach, Germany), as previously described (16) . Positively selected cells were 95-99% CD4 + or CD8 + by cytofluorometric analysis, and were lysed with guanidinium isothiocyanate. In other experiments, RNA was isolated from freshly isolated unstimulated PBMC.
Complementary were CCTCTGTTCTTCCTGCTAGCATGTGCC and CCAACGTAC-TCTGGTTGGCTTCCTTCA, respectively. The primer sequences for IL-2 and IL-10 and the reaction conditions for amplification of cytokine cDNA have been previously published ( 17) . Serial dilutions of MIMIC for the appropriate cytokine cDNA were added to each reaction, and substrate cytokine cDNA quantitated as outlined above for CD3 cDNA. Upon PCR amplification of serial twofold dilutions of sample cDNAs, a concomitant decrease in sample PCR product and increase in MIMIC PCR product was observed, indicating that our PCR conditions were not within the plateau phase of amplification. Specificity of PCR amplification was confirmed by transfer of PCR product to nylon membranes and hybridization with a radiolabeled oligonucleotide probe complementary to sequences internal to those recognized by the CD3-specific primers, as previously described ( 17) . Positive controls containing cytokine cDNA (from PHA-stimulated PBMC) and negative controls containing no cDNA were used in each set of reactions.
Measurement of cytokine concentrations by ELISA. For cells cultured in the presence of media alone or M. tuberculosis, supernatants were harvested after 24, 48, 72, and 96 h and stored at -70°C. Cytokine concentrations were measured by ELISA (IFN-y and IL-2, Genzyme Corp., Cambridge, MA; IL-4, Monoclonal Antibody Technology, Stockholm, Sweden; IL-10, Biosource International, Camarillo, CA). Cytokine concentrations are shown as the concentration in supernatants of M. tuberculosis-stimulated cells minus that in supernatants of cells cultured in media alone. In more than 95% of the cases, no cytokines were detected in supernatants of cells cultured in media alone. In the few remaining cases, low levels (< 100 pg/ml) of IFN-y and IL-10 were measured. Concentrations of IFN-y were maximal after 96 h of culture and are reported for that time point. Concentrations of IL-2 were determined after 24 h of culture. IL-4 was not detected in supernatants at 24, 48, 72, or 96 h. Concentrations of IL-10 were maximal at 24 h and are reported for that time point.
Modulation of proliferative responses and interferon-y production by anticytokine antibodies and by IL-12. PBMC from HIV-infected tuberculosis patients were cocultured with M. tuberculosis and proliferative responses determined as outlined above. In some cases, neutralizing antibodies to human IL-4 (Genzyme Corp.) and to human IL-10 (Biosource International) were added at 10 jg/ml to some wells. In other cases, recombinant human IL-12 (kind gift of Dr. Maurice Gately, Hofmann La Roche, Inc., Nutley, NJ) was added at 10 ng/ml. Supernatants for determination of IFN-y concentrations were harvested in some cases, as outlined above. As controls for the addition of anti-IL-4 or anti-IL-10, isotype control antibodies were also added to M. tuberculosisstimulated cells.
Statistical analysis. Continuous variables that were normally distributed were compared by the Student's t test. Variables that were not normally distributed were compared by the nonparametric Wilcoxon rank-sum test.
Results
Proliferative responses by M. tuberculosis-stimulated PBMC. PBMC from 16 HIV-infected tuberculosis patients and from 14 tuberculosis patients without HIV infection were stimulated in vitro with heat-killed M. tuberculosis. The proliferative response was significantly reduced in HIV-infected patients, compared to those without HIV infection (mean delta cpm 15,110±5,452, vs 62,593±15,626, P < 0.01). In 10 healthy tuberculin reactors with a protective immune response to M. tuberculosis, the mean delta cpm was 117,179±14,017. In HIVinfected patients, the mean delta cpm in eight patients with more than 100 CD4 cells/bld was 11,253±3,534, compared with 18,967±5,219 in eight patients with fewer than 100 CD4 cells/ Al. There was no correlation between the delta cpm and the CD4 cell count (r = 0.23), indicating that the reduced proliferative response was not simply due to a lack of CD4 cells.
Cytokine production by M. tuberculosis-stimulated PBMC. Concentrations of interferon-y in cell culture supematants were reduced in HIV-infected tuberculosis patients, compared with tuberculosis patients without HIV infection (822±336 pg/ml, vs 2,278±582 pg/ml, P = 0.004, Fig. 1 ). IL-2 was barely detectable (90+36 pg/ml for HIV-infected patients, vs 86±26 pg/ml for patients without HIV infection). IL-4 was not detected in any of the supernatants. IL-10 concentrations were comparable in patients with and without HIV infection (711±187 pg/ml vs 578±85 pg/ml). Thus, production of the type 1 cytokine IFN-y was reduced in HIV-infected patients, whereas production of the type 2 cytokine IL-10 was comparable to that in patients without HIV infection.
Cytokine (Fig. 3) . The cytokine profiles of sorted CD8 cells were also identical for the two groups (data not shown). These results indicate that coinfection with HIV did not alter type 1 or type 2 cytokine production per CD4 cell, and that the reduction in type 1 cytokine mRNA expression in HIV-infected tuberculosis patients reflected the depressed CD4 cell counts in these individuals. Modulation of proliferative responses in HIV-infected tuberculosis patients. We hypothesized that the reduced proliferative responses in HIV-infected tuberculosis patients may be mediated by the type 2 cytokines IL-4 and/or IL-10, which can inhibit antigen-induced proliferation by deactivation of antigenpresenting cells and downregulation of macrophage MHC class II expression (19) (20) (21) (22) (23) (24) . To evaluate this hypothesis, PBMC from HIV-infected tuberculosis patients were cocultured with M. tuberculosis, or with M. tuberculosis and neutralizing antibodies to IL-4 or to IL-10. In HIV-infected patients classified as -/ + / +, anti-IL-4 and IL-10 enhanced the proliferative response to influenza virus (18, 25) . We therefore analyzed our results separately for HIV-infected tuberculosis patients classified as -/+/+ and +/+/+. In both groups, anti-IL-4 had minimal effects on M. tuberculosis-induced proliferation (Fig.  4) . In contrast, anti-IL-10 enhanced proliferation in all 5 patients classified as -/+/+ and in 11 of 12 patients classified as + / + / + (Fig. 5, A and B) . In the 17 patients, mean delta cpm in response to M. tuberculosis increased from 18,456±5,211 to 40,883+ 11,320 with addition of anti-IL-10 (P = 0.006). Control experiments using isotype control antibodies for anti-ILIO did not affect M. tuberculosis-induced proliferation. Addition of anti-IL-4 or anti-IL-10 alone in the absence of M. tuberculosis did not result in cell proliferation. In 11 tuberculosis patients without HIV infection, addition of anti-IL-O0 augmented the proliferative response to M. tuberculosis in a few patients, but the change was not statistically significant for the group as a whole (Fig. 5 C, mean delta cpm 44,120± 15 ,829, vs 56,316±19,079, P > 0.05). These results suggest that the low proliferative responses to M. tuberculosis in HIV-infected tuberculosis patients are mediated through IL-10.
IL-12 favors development of Thl cells in vitro (26, 27) and in vivo (28, 29) , and can restore T cell proliferative responses to HIV envelope peptides (30) . We therefore evaluated the effects of recombinant IL-12 on the M. tuberculosis-induced proliferative response of PBMC from HIV-infected tuberculosis patients. IL- 12 enhanced the proliferative response in 2 of 5 patients classified as -1+1+, and in 7 of 12 patients classified as +1+1+ (Fig. 6) . However, the increase in mean delta cpm in response to M. tuberculosis with addition of IL-12 was not statistically significant (16,421±4,801 vs 24,060±7,086, P > 0.05). Addition of both anti-IL-O0 and IL-12 did not yield additive augmentation of the proliferative response, which were comparable with those obtained with addition of anti-IL-10 alone in seven out of eight patients (data not shown). In 10 tuberculosis patients with- Because anti-IL-10 and IL-12 enhanced the M. tuberculosisinduced proliferative response in some patients, we wished to evaluate the effect of these agents on the type 1 response. Concentrations of IFN-y in supernatants of M. tuberculosis-stimulated cells were significantly higher after addition of anti-IL-10 or recombinant IL-12 ( Fig. 7) , indicating that the type 1 response was enhanced. Because antibodies to IL-IO and recombinant IL-12 can induce natural killer cells to produce IFN-y (31-33), we stimulated PBMC with anti-IL-O0 or IL-12 alone, in the absence of M. tuberculosis. Under these conditions, the maximum concentration of IFN-y in supematants was 200 pg/ ml, which was insufficient to account for the marked increases in IFN-y production observed upon addition of anti-IL-10 or IL-12 to M. tuberculosis-stimulated PBMC.
Discussion
Persons with HIV infection are at markedly increased risk for development of disease from recent and remote infection with M. tuberculosis (34) (35) (36) . In addition, the manifestations of tuberculosis in HIV-infected persons are often severe and lifethreatening (1, 2 (37, 38) . Although the mechanism underlying this effect is uncertain, it is noteworthy that the putative mycobacterial virulence factor lipoarabinomannan, a heteropolysaccharide attached to the mycobacterial cell membrane, induces production of IL-10 (15), which in turn inhibits antigen-specific T cell proliferation and type 1 cytokine production in patients with leprosy (16) . Our results suggest that the reduced proliferative and type 1 responses in HIV-infected tuberculosis patients are mediated at least in part through IL-10. Anti-IL-10 markedly enhanced the M. tuberculosis-induced proliferative response in HIV-infected tuberculosis patients, whereas the effect was variable in tuberculosis patients without HIV infection, despite production of comparable levels of IL-10 by PBMC from both groups. Macrophages and/or T cells from HIV-infected patients may express higher levels of IL-10 receptors and therefore be more sensitive to the effects of IL-10 than are patients without HIV infection. Additional studies are needed to clarify this issue.
IL-4, a potent cross-regulatory cytokine produced by Th2 cells, inhibits development of Thl cells in vitro and in vivo. T cells cocultured with M. tuberculosis and IL-2 secrete a Thl cytokine pattern, but addition of IL-4 favors development of Th2 cells (39) . Similarly, in mice primed with a helminth infection to boost IL-4 production, subsequent challenge with M. tuberculosis results in a Th2 response (40) . Our PATIENT cell production of IL-4 is enhanced, and reduced proliferation and IL-2 production in response to influenza and tetanus are restored by neutralizing antibodies to IL-4. These disparities probably reflect differences in our patient populations and experimental systems. Clerici's patients were asymptomatic and were at an early stage of HIV infection before development of opportunistic infections, whereas our patients were at an advanced stage of HIV infection and were coinfected with M. tuberculosis. Clerici's patients had CD4 cell counts of 400-800/1l, but our patients had a mean CD4 cell count of 100/ gul. In addition, Clerici immunodeficiency, type 2 cells may be prominent, but as HIV disease progresses, immunosuppression may be mediated predominantly by macrophages that produce IL-10 and perhaps other immunosuppressive cytokines such as transforming growth factor-/9 (41) .
IL-12 has a wide range of immunostimulatory properties, including enhancement of cytotoxic T cell activity, T cell proliferation, natural killer cell activity, and IFN-y production (42- 
